Sector News

Jamere Jackson elected to Lilly Board of Directors

August 31, 2016
Life sciences

The board of directors of Eli Lilly and Company has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly’s board, he will serve on the Audit and Finance committees.

Jackson is currently chief financial officer of Nielsen Holdings plc (Nielsen).

“I am delighted to welcome Jamere Jackson to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Jamere brings a wealth of global financial experience, including a strong background in strategic planning. His experience at Nielsen will also provide an important perspective to our business and help broaden our understanding of consumer markets and strategies.”

Prior to joining Nielsen in 2014, Jackson was with General Electric (GE). His last position there was vice president and chief financial officer for GE Oil & Gas, drilling and surface division. In that role, he was responsible for driving financial rigor, developing strategy and implementing change across the drilling and surface portfolio.

Jackson joined GE in 2004 as the chief financial officer for Global Business Services. He then became chief financial analyst for GE Corporate before being promoted to chief financial officer for GE Aviation Military Systems. Next, he was named chief financial officer for GE Aviation Systems, where he led a global team focused on expanding GE’s jet-engine business beyond its core products.

Jackson’s experience also includes positions at First Data Corporation, Total System Services, Pizza Hut Inc., and Procter & Gamble Company. He is a certified public accountant and received his undergraduate degree in finance and business economics from the University of Notre Dame.

Source: Eli Lilly and Company

comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach